These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18454994)

  • 1. Conversion therapy to everolimus in renal transplant recipients: results after one year.
    Giron F; Baez Y; Niño-Murcia A; Rodríguez J; Salcedo S
    Transplant Proc; 2008 Apr; 40(3):711-3. PubMed ID: 18454994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs.
    Araki M; Flechner SM; Ismail HR; Flechner LM; Zhou L; Derweesh IH; Goldfarb D; Modlin C; Novick AC; Faiman C
    Transplantation; 2006 Feb; 81(3):335-41. PubMed ID: 16477217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
    Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
    Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
    Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
    Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to everolimus in maintenance patients--current clinical strategies.
    Pohanka E
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
    Vítko S; Margreiter R; Weimar W; Dantal J; Viljoen HG; Li Y; Jappe A; Cretin N;
    Transplantation; 2004 Nov; 78(10):1532-40. PubMed ID: 15599319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis.
    Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M
    Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.